Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DORZOLAMIDE HCL & TIMOLOL MALEATE

All products: Limited Use (codes 310, 393)

Other products in the same Health Canada class (S01ED) — coverage varies; not interchangeable

  • Betaxolol (Betoptic S): general benefit
  • Levobunolol (Betagan): general benefit
  • Timolol (Timoptic-XE): general benefit, Not a benefit
  • Brimonidine + timolol (Apo-Brimonidine-Timop): limited Use 310, 393
  • Brinzolamide + timolol (Azarga): limited Use 310, 393
  • Latanoprost + timolol (Xalacom): limited Use 310, 393

11 more in the class list below

Cosopt · DIN 02240113 · 2% & 0.5% · Oph Sol

Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Savings card: RxHelp ONE lists Cosopt (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Cosopt · DIN 02240113 Manufacturer: Elvium Life Sciences; listing date 2000-01-17 Health Canada: Marketed since 2020-08-31 · brand COSOPT · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 5 MG/ML, DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML · company Elvium life sciences · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $2.0951 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63627 · Verify on the e-Formulary ↗ (DIN 02240113)

Source record
DIN 02240113: Cosopt Raw flags: sec12=Y, sec3=Y Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id ELV Source form: Oph Sol; strength: 2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $9.8639; ministry $2.0951 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240113 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63627
Interchangeable products
Apo-Dorzo-Timop · DIN 02299615 · $2.0951 Co Dorzotimolol · DIN 02404389 · $2.0951 Dorzolamide-Timolol · DIN 02522020 · $2.0951 Jamp Dorzolamide-Timolol · DIN 02457539 · $2.0951 M-Dorzolamide-Timolol · DIN 02537796 · $2.0951 Med-Dorzolamide-Timolol · DIN 02437686 · $2.0951 Mint-Dorzolamide/Timolol · DIN 02443090 · $2.0951 Riva-Dorzolamide/Timolol · DIN 02441659 · $2.0951 Sandoz Dorzolamide/Timolol · DIN 02344351 · $2.0951
Shortage status: resolved shortage (ended 2025-07-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240113
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

· 3 products · Limited Use, codes 310, 393 · strengths: 0.2% & 0.5% · Oph Sol-10mL Pk

BRINZOLAMIDE & TIMOLOL MALEATE

· 1 products · Limited Use, codes 310, 393 · strengths: 1% & 0.5% · Oph Susp-5mL Pk

LATANOPROST & TIMOLOL MALEATE

· 9 products · Limited Use, codes 310, 393 · strengths: 50mcg/mL & 5mg/mL · Oph Sol-2.5mL Pk

TIMOLOL MALEATE & TRAVOPROST

· 4 products · Listed, not a benefit (1), Limited Use, codes 310, 393 (3) · strengths: 0.5% & 0.004% · Oph Sol, Oph Sol-5mL Pk

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol

BRINZOLAMIDE

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:36 and 20 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS COSOPT® (dorzolamide hydrochloride and timolol maleate) and COSOPT® preservative-free (without benzalkonium chloride as the preservative) are indicated in the treatment of elevated intraocular pressure (IOP) in patients with: • ocular hypertension • open-angle glaucoma when concomitant therapy is appropriate. COSOPT preservative-free is indicated in patients who may be sensitive to a preservative, or for whom the use of a preservative-free formulation is otherwise advisable. For details please also refer to the 4 DOSAGE AND ADMINISTRATION section as well as to the 14 CLINICAL TRIALS section. 1.1 Pediatrics Pediatrics (<18 years of age): Safety and effectiveness in children have not been established. No data are available to Health Canada; therefore, an indication for pediatric use has not been authorized. 1.2 Geriatrics Geriatrics (>65 years of age): No overall differences in effectiveness or safety were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00073687.PDF PM date: OCT 25, 2016 Source product: COSOPT; DIN 02240113; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.